Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 16/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 16/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 15/20 | 0.60 |
| ▸ | TSHR | P16473 | 13/20 | 0.60 |
| ▸ | LMNA | P02545 | 7/20 | 0.60 |
| ▸ | USP2 | O75604 | 6/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | APLNR | P35414 | 1/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20252546 | 0.86 | SMN1; SMN2 (0.50) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL29669157 | 0.82 | L3MBTL1 (0.74) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL16109009 | 0.82 | L3MBTL1 (0.74) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL20238802 | 0.82 | CYP1A2 (0.63) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL16368537 | 0.82 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL20237993 | 0.81 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL30711679 | 0.81 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL1690631 | 0.80 | CYP1A2 (0.68) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL15465606 | 0.79 | CYP1A2 (0.69) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 | |
| SCHEMBL3452299 | 0.79 | CYP1A2 (0.69) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250042917-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12139496-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024046471-A1 | USP1 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2024-03-07 | — | — | WO | disclosed |
| WO-2023028056-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| EP-2773637-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2014-09-10 | — | — | EP | disclosed |
| CN-104024251-A | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC | 2014-09-03 | — | — | CN | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-8772293-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2014-07-08 | — | — | US | disclosed |
| US-20140045862-A1 | Cycloalkane Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
| EP-2590951-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042917-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | CYP1A2 1597/4885CYP3A4 1263/4885CYP2D6 577/4885 |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | CYP1A2 2951/4885CYP3A4 4002/4885CYP2D6 3723/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | CYP1A2 2059/4885CYP3A4 1543/4885CYP2D6 1225/4885 |
| US-20120010182-A1 | Chemical Compounds | SCN1A, SCN1B, CACNA1E | CYP1A2 643/4885CYP3A4 849/4885CYP2D6 580/4885 |
| US-12209075-B2 | Pyridine-sulfonamide derivatives as sodium channel inhibitors | SCN1B, CACNA1A, SCN1A | CYP1A2 1610/4885CYP3A4 2156/4885CYP2D6 518/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | CYP1A2 1091/4885CYP3A4 505/4885CYP2D6 321/4885 |
| US-20140045862-A1 | Cycloalkane Derivatives | TRPV1, TRPA1, SCNN1A | CYP1A2 2162/4885CYP3A4 3744/4885CYP2D6 1945/4885 |
| US-20250115576-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | F12, REN, ZYX | CYP1A2 1182/4885CYP3A4 1611/4885CYP2D6 83/4885 |
| US-12139496-B2 | Therapeutic compounds and methods of use thereof | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C3AR1 | CYP1A2 1597/4885CYP3A4 1263/4885CYP2D6 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.